Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that the U.S. Patent and Trademark Office has issued a new patent covering its lead investigational therapy, istaroxime, for intravenous ...

Thanks to medical advancements, heart attack deaths have dropped nearly 90% in the last 50 years. But deaths from these ...

In this high-yield, clinically focused session, Dr. Steven L. Cohn, one of the leading experts in perioperative medicine, ...

Decreases seen in mortality for acute MI, ischemic heart disease, while increases seen for mortality from other heart disease subtypes ...

If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039 ...

From 1970 to 2022, there was a decrease in heart disease mortality overall, but an increase in mortality from other heart ...

The Medical Center at Caverna, The Medical Center at Franklin and The Medical Center at Scottsville have all earned The Joint Commission’s Gold Seal of Approval for Acute Heart Attack Ready ...

Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and ...

BOWLING GREEN, Ky. (WBKO) - Three rural hospitals have earned The Joint Commission’s Gold Seal of Approval® for Acute Heart ...

In 1970, ischemic heart disease—mostly heart attacks—accounted for 91% of heart-related deaths. Today, that number has fallen ...

Following a heart transplant, patients must undergo surgical biopsies so that clinicians can monitor for signs of organ rejection. A new study shows the promise of a biomarker that could allow doctors ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with AMI.